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Abstract
Detecting treatment efficacy using cognitive change in trials of cerebral small vessel disease (SVD) has been challenging,
making the use of surrogate markers such as magnetic resonance imaging (MRI) attractive. We determined the sensitivity
of MRI to change in SVD and used this information to calculate sample size estimates for a clinical trial. Data from the
prospective SCANS (St George’s Cognition and Neuroimaging in Stroke) study of patients with symptomatic lacunar
stroke and confluent leukoaraiosis was used (n¼ 121). Ninety-nine subjects returned at one or more time points.
Multimodal MRI and neuropsychologic testing was performed annually over 3 years. We evaluated the change in
brain volume, T2 white matter hyperintensity (WMH) volume, lacunes, and white matter damage on diffusion tensor
imaging (DTI). Over 3 years, change was detectable in all MRI markers but not in cognitive measures. WMH volume and
DTI parameters were most sensitive to change and therefore had the smallest sample size estimates. MRI markers,
particularly WMH volume and DTI parameters, are more sensitive to SVD progression over short time periods than
cognition. These markers could significantly reduce the size of trials to screen treatments for efficacy in SVD, although
further validation from longitudinal and intervention studies is required.
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Introduction
Cerebral small vessel disease (SVD) is a term used to
describe a group of pathologic processes that aﬀect the
perforating cerebral arterioles and capillaries resulting
in brain injury to the subcortical grey and white
matter.1 A number of brain parenchymal pathologies
can occur, including small deep infarcts, microbleeds,
areas of diﬀuse gliosis, ischemic demyelination and
axonal loss corresponding to regions of radiologic leu-
koaraiosis, and diﬀuse brain atrophy.2 Clinically SVD
presents with lacunar strokes, which represent approxi-
mately 20% of all ischemic strokes, and it is also the
major cause of vascular cognitive impairment. In add-
ition, it appears to interact with Alzheimer’s disease,
exacerbating the degree of clinical impairment.3
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Thus SVD is an enormous health burden that leads to
signiﬁcant neurologic and cognitive decline. Despite its
importance, there are few validated treatments for
SVD. Reasons for this include a lack of understating
of the pathogenesis and the challenges of performing
large clinical trials in the condition including the
insensitivity of cognitive scores to change.4 The use of
surrogate markers in which novel treatments can be
evaluated for potential eﬃcacy before large clinical
end point trails is attractive and magnetic resonance
imaging (MRI) has been suggested as such a surrogate.
MRI is essential to diagnosis of SVD. Common fea-
tures seen on conventional MRI include lacunes, T2
white matter hyperintensities (WMHs), cerebral micro-
bleeds (CMBs), perivascular spaces, and brain atro-
phy.2 More advanced techniques using diﬀusion
tensor imaging (DTI) has been shown to be sensitive
to tissue damage showing abnormalities in apparently
normal appearing white matter.5,6 These abnormalities
on MRI may be potentially useful surrogate disease
markers that can used to assess therapeutic approaches.
If these MRI parameters are to be used as reliable sur-
rogate markers in clinical trials, they must fulﬁll the
following criteria: (1) they must be able to predict clin-
ical outcome, as changes induced by a therapy on a
surrogate marker are expected to reﬂect changes in a
clinically meaningful end point; (2) change in a surro-
gate marker must be detectable prospectively; and (3)
the sample size required to show therapeutic eﬃcacy
should be feasible in the setting of a clinical trial.7
The sample size is dependent on a number of factors,
including the magnitude of the change in the marker
detectable prospectively and the variability of
measurements.
Several potential MRI markers in SVD are known to
predict changes in a clinical outcome measure (e.g., cog-
nitive impairment, progression to dementia, or disabil-
ity; Table 1). Whole brain volume has been shown to
correlate strongly with cognitive impairment in several
cross-sectional8,9 and longitudinal10 studies. Brain
volume change has also been shown to correlate with
disability scales in Cerebral Autosomal Dominant
Arteriopathy with Subcortical Infarcts and
Leucoencephalopathy (CADASIL), a genetic form of
SVD.11 T2 WMHs, have usually shown signiﬁcant
associations with cognitive impairment cross-
sectionally8 and longitudinally,4 although the correl-
ation has been weaker or sometimes absent in subjects
with symptomatic SVD and leukoaraiosis8,9 (Table 1).
DTI parameters in normal-appearing white matter have
consistently been shown to correlate with cognitive per-
formance in a number of SVD cohorts.5,12,13 Finally,
lacunes are also an important predictor of cognitive
impairment in SVD.14 Patients with incident lacunes
are known to have a faster rate of cognitive decline.15
Abnormalities on brain imaging often exist long
before symptoms occur and may have a faster rate of
progression than cognitive outcome measures. Using
them as surrogate markers could signiﬁcantly reduce
the size, duration, and cost of clinical trials in SVD.
In this study, we use multimodal serial brain (MRI)
to prospectively evaluate the rate of change of some
of these proposed MRI markers in established SVD;
in particular brain atrophy, T2 WMH, lacunes and
DTI parameters. We then used this data to determine
the sample sizes required to demonstrate a reduction in
the rate of progression of these MR abnormalities in a
hypothetical clinical trial and compared these estimates
with estimates if cognitive measures were used.
Materials and Methods
Patients
Patients with SVD were recruited as part of the pro-
spective St George’s Cognition and Neuroimaging in
Stroke (SCANS) study.8 Recruitment was from acute
stroke units or outpatient stroke clinics in three hos-
pitals covering a contiguous catchment area in South
London (St George’s, King’s College, and St Thomas’
Hospitals). Inclusion criteria comprised a clinical lacu-
nar stroke syndrome16 with an anatomically corres-
ponding lacunar infarct on MRI in addition to
conﬂuent WMH on MRI (Fazekas grade 2).17
Exclusion criteria were: any cause of stroke mechanism
other than SVD (e.g., cardioembolic source or extra- or
intra-cerebral artery stenosis of >50%), other major
central nervous system disorders, major psychiatric dis-
orders, any other cause of white matter disease, contra-
indications to MRI, or non-ﬂuent in English. The study
was approved by Wandsworth research ethics commit-
tee, and all patients gave written informed consent.
MRI acquisitions and cognitive assessments were per-
formed at least 3 months after the last stroke to exclude
acute eﬀects on cognition. All patients were also
screened for cardiovascular risk factors, including
hypertension (deﬁned as systolic blood pressure
>140mmHg or diastolic >90mmHg or treatment with
antihypertensive drugs), hypercholesterolemia (deﬁned
as a serum total cholesterol >5.2mmol/l or treatment
with a statin), diabetes mellitus, and smoking.
Subjects were invited back annually for cognitive
testing and MRI scanning. In this analysis, follow-up
data up to the third follow-up was used, providing a
maximum of four data points per individual.
MRI Acquisition
Images were acquired on a 1.5T Signa HDxt scanner
(General Electric, Milwaukee, WI, USA) with
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maximum gradient amplitude of 33mT/m and a pro-
prietary head coil. All image sequences were acquired
across the whole brain and total imaging time was
approximately 45minutes. Patients were placed in the
head coil in a neutral position with an alignment
marker at the nasal bridge to standardize head position.
Minimal movement was ensured by use of foam pads
and a velcro strap across the forehead.
The imaging protocol included: (1) Fluid Attenuated
Inversion Recovery (FLAIR) sequence—TR/TE/
TI¼ 9,000/130/2,200ms, ﬁeld-of-view (FOV)¼ 240
240mm2, matrix¼ 256 192, 28 axial slices of 5-mm
thickness. (2) Spoiled gradient echo recalled T1-
weighted (SPGR) 3D coronal sequence—TR/TE¼
11.5/5ms, FOV¼ 240 240mm2, matrix¼ 256 192,
ﬂip angle¼ 18o, 176 coronal slices of 1.1-mm thickness
reconstructed to an in plane resolution of 1.1mm. (3)
DTI—Axial single shot spin echo planar images (EPI;
TE¼ 93.4ms, TR¼ 15,600ms) were acquired to
achieve whole brain coverage (2.5mm3 isotropic
voxels; FOV¼ 240 240mm2, acquisition matrix¼
96 96), following four acquisitions without diﬀusion
weighting (b¼ 0 s/mm), diﬀusion-sensitized images
were acquired with gradients applied (b¼ 1000 s/mm)
in 25 non-collinear directions. This was repeated to
acquire a further four b¼ 0 s/mm images and the nega-
tive of the 25 directions. Diﬀusion-weighted images
were realigned to remove eddy current distortions
using the FSL Linear Image Registration Tool
(FLIRT, FMRI Software Library, FSL version 4.1;
FMRIB Analysis Group, Oxford, UK, http://
www.fmrib.ox.ac.uk/fsl). The geometric average of the
positive and negative acquisitions was taken to elimin-
ate gradient cross-terms. The eight b¼ 0 s/mm images
were co-registered and averaged to give a T2-weighted
echo planar image (henceforth termed b0).
Estimation of Longitudinal Brain Volume Change
Brain volume at baseline was calculated using a fully
automated program, SIENAX (Cross-sectional
Structural Image Evaluation using Normalisation of
Atrophy; www.fmrib.ox.ac.uk/fsl) on T1-weighted
images. This program computes brain volume relative
to normalized skull size. Longitudinal changes in global
brain volume were estimated from the T1-weighted
images for each subject using an automated image ana-
lysis tool SIENA (Structural Image Evaluation using
Normalisation of Atrophy; www.fmrib.ox.ac.uk/fsl).18
This tool was used as SVD is a diﬀuse neurodegenera-
tive disease and SIENA provides a sensitive measure of
global volume loss. SIENA brain volume change has
also been shown to be a feasible outcome measure in
clinical trials in multiple sclerosis19 and Alzheimer’s dis-
ease.20 SIENA estimates the percentage of brain
volume change (PBVC) between two input images
and was applied here to provide a global estimate of
PBVC between each time point. Brain volume at each
time point was then calculated using the baseline brain
volume and the PBVC between each time point.
Diffusion MRI Analysis
Diﬀusion tensor elements were ﬁtted at each voxel
using DTIﬁt in FSL www.fmrib.ox.ac.uk/fsl, and
mean diﬀusivity (MD) and fractional anisotropy (FA)
maps were calculated.
Diﬀusion parameter histograms were then obtained
in white matter using the following method. T1-
weighted images were segmented using New Segment
in SPM12 into isotropic (1mm3 voxel resolution) grey
matter (GM), white matter (WM), and cerebrospinal
ﬂuid (CSF) tissue classes. These segmentations were
used to estimate deformations to a group-average tem-
plate generated from the data cohort using the Shoot
toolbox in SPM12.21 The T1-weighted and FLAIR
images were skull-stripped using the segmentations at
a threshold of 0.1 and warped to the common group-
average template. These were used to create popula-
tion-speciﬁc Tissue Probability Maps (TPMs) using a
modiﬁed multivariate mixture of Gaussians.22
This technique increases segmentation accuracy across
the cohort and provides TPMs for WMH from the
FLAIR and T1-weighted images, allowing automatic
segmentation at an individual level. These TPMs were
used to replace the default SPM TPMs, and New
Segment was re-run on the native space images to gen-
erate improved segmentations for GM, WM, and CSF,
while also providing a WMH tissue class. The WMH
segmentation maps were binarized at an individual set
threshold by checking each of the results manually to
ensure accurate correspondence. The binarization
threshold was performed without referring to previous
time points. Results were manually reﬁned where neces-
sary to optimize accuracy, with good intra- and
inter-rater reliability (Pearson’s intraclass correlation
coeﬃcient 0.98 and 0.99, respectively, deﬁned on a ran-
domly selected group of 20 scans between two raters
(CL and EZ)). An additional step was performed to
repair the segmentations for regions of tissue damage.
This was motivated by the observation that regions
aﬀected by pathology are frequently misclassiﬁed
during routine segmentation. For example, regions of
gliosis are misclassiﬁed as CSF and regions of WMH as
GM leading to erroneous deformation estimations and
subsequent inaccuracies in estimating warps to the
group-average space. For this reason, WMH regions
were automatically reclassiﬁed as WM and any errone-
ously classiﬁed tissue was removed from the GM and
CSF segmentation maps.14
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Aﬃne transformations, followed by non-linear
transformations (using the FMRIBs Non-linear Image
Registration Tool (FNIRT)) were computed by regis-
tration of the T1-weighted images to the b0 image of
each subject and applied to the above segmentation
maps to obtain masks of brain tissue in b0 space.
Voxels were included in the masks if the probability
of being GM or WM or WMH was >0.5. CSF voxels
were removed using thresholds based on the diﬀusion
properties of CSF (MD values of >0.0026mm2/s were
considered to contain CSF and excluded from the ana-
lysis). The diﬀusion characteristics of the WM tissue
class were evaluated for the purposes of this study.
MD and FA histograms in voxels representing WM
were calculated. For each subject, a histogram for MD
and FA was computed (bin widths: MD 0.000004mm2/s,
FA 0.01; upper limit: MD 0.004mm2/s, FA 1.0) for each
DTI voxel identiﬁed by the WMmask image. To correct
for diﬀerences in brain volume, each histogram was nor-
malized by the total number of voxels present with the
WM mask. For each MD histogram, the normalized
frequency of pixels at the peak height (MD NPH) was
obtained and used for further analysis as these were
deemed to be the most stable measurements. These par-
ameters have been cross-sectionally shown to have asso-
ciations with cognition in a SVD population.8
Estimation of Longitudinal WMH Volume Change
WMH masks were created using the above technique
from the FLAIR images. The volumes at each time
point were calculated in individual subject space by
summing the binarized corrected segmentations.
Three measurements were calculated, total brain
volume (Grey Matter (GM)þWhite Matter (WM)),
WMH volume, and WMH volume as a percentage of
total brain volume (WMH/total brain volume 100).
The latter value was used for further analysis as brain
volume changes with time and a reduced WM volume,
for example, may underestimate growth of the WMHs.
In a further step, we performed a scan–rescan test on
two patients to determine the eﬀect of changing head
position on WMH volumes and found these to be iden-
tical using the automated technique.
Identification of Lacunes
Lacunes were manually identiﬁed in native subject
space at each time point by a consultant neuroradiolo-
gist, using T1-weighted, T2-weighted, and FLAIR
images. A lacune was deﬁned as a CSF ﬁlled cavity, 3
to 15mm in diameter with a surrounding rim of FLAIR
hyperintensity.16 Cavity size thresholds were chosen as
lesions that are <3mm in diameter are more likely to be
perivascular spaces than lacunes and cavities >15mm
are less likely to reﬂect an underlying SVD etiology.16
For the longitudinal analysis, the images were ﬁrst
registered to a group average template. Our neurora-
diologist used these registered images to identify new
lacunes.
Neuropsychologic Assessment
Cognitive assessment was carried out annually using
well-established standardized tests to include measures
sensitive to the pattern of cognitive impairment asso-
ciated with SVD. Premorbid Intelligent Quotient was
estimated using the National Adult Reading Test-
Restandardized.23 Tasks were grouped into broad cog-
nitive functions: executive function and processing
speed.
Executive function: Trail making test, (Matrix B)
(Reitan 1996) Modiﬁed Wisconsin Card Sorting
Test,24 and Phonemic Fluency (FAS).25
Processing speed: Wechsler Adult Intelligence Scale-
III (Wechsler, 1997 a) Digit symbol substitution,26
Speed of Information Processing Task,27 and
Grooved Pegboard Task.28
Task performance was age scaled using manually
published normative data, transformed into z-scores,
and aggregated to construct the cognitive indices by
averaging across the component test measures for
each subject. For further details on the cognitive assess-
ment, please refer to Lawrence et al.8
Statistical Analysis
Because of the inherited hierarchical nature of the data
imposed by multiple measurements per patient, we use
Linear Mixed Eﬀects (LME) modeling to estimate
change over the follow-up period in our MRI markers
and cognitive measures.29 Following graphical inspec-
tion of the raw data, it was reasonable to assume amulti-
variate normal distribution as well as linearity of change
with time. Speciﬁcally, we used a random intercept and
random slopes model, which permits the estimation of
an average slope across the whole cohort while allowing
for inter-individual variability.29 The average slope rep-
resents the average annual change in a measurement and
can be used for estimation of sample sizes. A Bayesian
approach for statistical inference has been used and the
parameter estimates are summarized as the means of
their distribution and the uncertainty as their 95% cred-
ible interval (95%CI). This inferential approach accom-
modates for patient drop-out during the follow-up with
the assumption that unobserved measurements are miss-
ing at random (MAR). TheWinBUGS package (version
1.4.3, MRC Biostatistics Unit, Cambridge Institute of
Public Health, Cambridge Biomedical Campus,
Cambridge, UK) was used for estimation.
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Sample size estimations for brain volume, WMH
volume, DTI measures, and cognition were carried
out using the longpower statistical package in R version
3.02 (http://www.R-project.org/) by using the estimated
values for the intercept and slope variance and the resi-
dual variance.30,31 The input for these calculations is
presented in Table 3.
For lacunes, we deﬁned the event as the occurrence
of more lacunes than the number at baseline and the
data have been modelled as for a binary outcome. We
estimated the odds ratios of the event in association
with the baseline number of lacunes and hence the pre-
dicted probability of developing more lacunes than the
number found at the baseline. The proportion of
developing new lacunes at some point during the
follow-up period was then determined, and sample
sizes were calculated for a percentage reduction in the
average probability of having one or more new lacunes
during the 3-year follow-up period.
In clinical trials, MRI data are often only available
from two time points, baseline and ﬁnal follow-up. We
therefore used LME models to estimate average slopes
using data only from two time points (baseline and 2
years, baseline and 3 years). All patients were included
in the model as described above. Sample size estima-
tions using data from two time points was compared
with sample sizes using data from all four time points.
We also investigated the eﬀect of missing data on the
original estimates provided under the MAR assump-
tion by using a simultaneous model having as compo-
nents the random eﬀect model as originally considered
and a random eﬀects logistic model with ‘missingness’
as a response (a binary longitudinal response where 1
designates the absence of a measurement for any reason
and 0 its presence). This approach allowed us to inves-
tigate the relationship between data missing at follow-
up and baseline measurements as well as the slope.
Results
Patient Demographics
Of the 121 participants at baseline in the SCANS study,
99 subjects returned at one or more time points: 98 at
year 1, 77 at year 2, and 70 at year 3 (Table 2). One
subject attended the baseline and missed the year 1
follow-up but attended all subsequent sessions. Four
subjects missed the year 2 follow-up but subsequently
attended at year 3. Of the 22 subjects who did not have
follow-up MRI, 7 subjects died, 10 subjects formally
withdrew from the study, 4 were lost to follow-up,
and 1 declined further MRI. Demographics at baseline
are shown in Table 2. Patients who left the study (for
any reason) had a higher lacune load (P< 0.013), a
higher mean Rankin disability score (P< 0.026), and
a lower mean Mini Mental Test Examination
(P< 0.004) score at baseline when compared with
patients who attended all time points. There were, how-
ever, no signiﬁcant diﬀerences in baseline brain volume,
diﬀusion parameters, or other demographic
characteristics.
Table 2. Patient demographics at baseline.
Demographics and risk factors N¼ 120
Mean age (s.d.), years 70 (9.8)
Mini Mental test score (mean (s.d.)) 27.6 (2.7)
Sex
Female 42 (35.0%)
Male 78 (65.0%)
Hypertension
No 9 (7.5%)
Yes 111 (92.5%)
Hypercholesterolemia
No 17 (14.2%)
Yes 103 (85.8%)
Smoker
Never 55 (45.8%)
Current 23 (19.2%)
Ex-smoker 42 (35.0%)
Treated diabetes mellitus
Yes 22 (18.3%)
No 96 (80.0%)
Diet control 2 (1.6%)
Rankin disability score
0 38
1 48
2 15
3 16
4 3
MRI measures at baseline (per subject)
Average (95% CI) number of lacunes 4 (4, 5.1)
Average (95% CI) WMH load as the
pecentage of total normalized
brain volume
3.72 (3.16, 4.28)
Average (95% CI) normalized brain
volume in ml
1295 (1279.00,
1312.00)
Abbreviations: CI, credibility interval; WMH, white matter hyperintensity.
Hypertension was defined as systolic blood pressure >140mmHg or
diastolic >90mmHg or those on antihypertensive treatment.
Hypercholesterolemia was defined as a serum total cholesterol
>5.2mmol/l or treatment with a statin.
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Brain Volume
Over the course of the observational period, there was
strong evidence of a decrease in brain volume. The
average (95% credibility interval) annual brain
volume change was equal to 8.86m/s (10.67,
7.05 or 0.69% of baseline per year; Table 3;
Figure 1).
WMH Volume
Larger WMH volume at baseline was associated with a
faster rate of growth. Over the course of the observa-
tional period, there was a strong evidence of growth in
WMH volume. The average (95% credibility interval)
annual change in WMH volume was equal to 0.80%
(0.67, 0.95; Table 3; Figure 1).
Table 3. Change in MRI and cognitive indices estimated using a random intercepts and random slopes model fit to the data.
Parameter Mean intercept Mean slope Slope variance Residual variance
MRI measures
Brain volume (ml) 1295.00 (1279.00,
1312.00)
8.83 (10.61,
7.01)
28.15 (5.63, 54.68) 182.10 (145.90,
227.40)
White matter hyperintensity (%) 3.72 (3.16, 4.28) 0.80 (0.67, 0.95) 0.43 (0.27, 0.65) 0.12 (0.09, 0.15)
MD peak height 0.015 (0.015, 0.016) 3.87 104
(4.51 104,
3.24 104)
1.55 104
(8.59 105,
2.81 104)
5.16 104
(4.62 104,
5.77 104)
Cognitive indices
Executive function 0.92 (1.12,
0.73)
0.0362 (0.083, 0.0
10)
0.020 (0.053,
0.0384)
0.13 (0.10, 0.16)
Processing speed 0.81 (0.98,
0.64)
0.014 (0.053,
0.024)
0.013 (0.022, 0.026) 0.092 (0.073, 0.126)
Abbreviations: MD, mean diffusivity; MRI, magnetic resonance imaging. 95% credible intervals are shown in brackets.
Figure 1. Plots showing individual trajectories in magnetic resonance imaging (MRI) markers showing a decrease in mean diffusivity
(MD) normalized peak height (MD NPH), a decrease in brain volume and an increase in white matter hyperintensity volume (WMH)
over the 3-year follow-up period. Time points are shown on the x axis. The average slope is shown in red with credibility intervals.
There is only a minimal change in slope when missing data are accounted for in simultaneous models (shown in blue). MAR, missing at
random.
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Diffusion Imaging
MD NPH: There was strong evidence of a decrease in
MD NPH over the course of the observational period.
The average (95% credibility interval) annual change
was equal to 3.87 104 (4.51 104, 3.24
104) (or 2.54% with respect to baseline per year)
(Table 3; Figure 1).
Lacunes
There were 98, 77, and 70 subjects with suitable
T1-weighted images at time points 1, 2, and 3, respect-
ively. Sixteen out of the 98 subjects had one or more
new lacunes after 1 year of follow-up; 17 out of the 77
subjects had one or more new lacunes after 2 years of
follow-up. Twenty out of the 70 subjects had one or
more new lacunes after 3 years of follow-up. The
number of lacunes at baseline was positively associated
with a higher probability of new lacunes at follow-up.
After modeling the baseline data using a Poisson distri-
bution, the mean (95% credibility interval) number of
baseline lacunes was estimated to be 4 (4.2, 5.1).
However, 50% of subjects had 2 lacunes at baseline.
The predicted probability of developing >4 lacunes
over the 3-year follow-up period was estimated to be
0.21 (0.13, 0.31).
Cognition
Executive function: There was no evidence of change in
executive function (Z-score) over the course of the
observational period. The average (95% credibility
interval) annual change was equal to 3.62 102
(8.33 102, 1.07 102; Table 3).
Processing speed: There was no evidence of change
in processing speed (Z-score) over the course of the
observational period. The average (95% credibility
interval) annual change was equal to 1.44 102
(5.35 102, 2.47 102; Table 3).
Sample Size Calculations
Sample sizes are calculated for a hypothetical trial of
3-year trial duration with measurements taken every
year and evenly in time. A balanced design is assumed.
For brain volume, WMH growth, and MD NPH, the
minimum sample size per arm required to detect a 30,
25, 20, and 15% treatment eﬀect at 80% power was
estimated. The results are shown in Table 4.
For lacunes, the sample size was calculated for a
percentage reduction in the average probability of
having >4 lacunes at follow-up. For a 3-year trial dur-
ation, the minimum sample size required to detect a 30,
25, 20, and 50% treatment eﬀect at 80% power was
572; 842; 1,345; and 2,442; respectively (Table 4).
Sample size estimates in the hypothetical scenario
that only two MRI scans were performed during the
trial are shown in Table 5. Estimates are given for a
trial with a 2- and 3-year follow-up. Estimates were not
greatly diﬀerent from those using the LME modeling
on all time points, particularly when 3-year follow-up
data were used.
Sensitivity Analysis
The simultaneous models, which take ‘missingness’ into
account, did not reveal dramatic changes in the average
rate of change for the MRI measures. The 95% cred-
ibility intervals (for both intercepts and slopes) overlap
to a large extent with the original MAR model
(Supplementary Table S1; Figure 1). The simultaneous
model for MD NPH showed the largest departure from
its original MAR slope estimate of 0.039 (0.045,
0.032) to 0.045 (0.07, 0.018) (Supplementary
Table S1, Figure 1).
The analysis showed that older patients were more
likely to drop out of the study. There was no strong
evidence that baseline WMH volume, brain volume or
diﬀusion parameters were predictive of dropout how-
ever we found that patients with a faster increase in
WMH volume were more likely to drop out at subse-
quent time points (Supplementary Table S1).
Baseline WMH volume was positively correlated
with the rate of WMH growth. Larger brain volumes
at baseline were also correlated with a faster rate of
atrophy. There was, however, no relationship between
baseline diﬀusion parameters and their rate of change
(Supplementary Table S1).
Table 4. The predicted minimum sample size per arm (for MRI
and cognitive measures) (power¼ 0.0.8 and type 1 error¼ 0.05)
for a hypothetical clinical trial of 3-year duration assuming a
balanced design with measurements taken every year evenly in
time to test hypothetical treatment effects of 30, 25, 20, 15, and
10% in the intervention group.
Sample size (per arm) to
test treatment effects of:
Parameter 30% 25% 20% 15%
MRI measures
WMH volume 124 178 279 496
Brain Volume 145 208 325 578
Lacunes 572 842 1,345 2,442
MD normalized peak height 128 185 289 513
Cognitive indices
Executive function 6,135 8,834 13,803 24,539
Processing speed 26,369 37,972 59,331 105,478
Abbreviations: MD, mean diffusivity; MRI, magnetic resonance imaging;
WMH, white matter hyperintensity.
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Discussion
This prospective longitudinal study in symptomatic
SVD has shown that change in MRI markers is detect-
able over a 3-year follow-up period. In contrast over
the same time period there was no evidence of change
detectable in cognitive measures. The eﬀect of age on
cognitive and MRI measures was deemed negligible. It
follows that sample size estimates of the number of
patients needed to demonstrate a treatment eﬀect in
an interventional trial are much smaller when using
MRI markers as an end point.
The lack of cognitive change is consistent with the
recent results of the SPS3 trial in approximately 3,000
patients with MRI conﬁrmed lacunar stroke.32 Over a
median follow-up of 3 years, there was very little cog-
nitive change. Why cognitive change is so diﬃcult to
detect in such a cohort, when it is easily detectable in a
high proportion of individuals in cross sectional stu-
dies8 is unclear. Possible factors may include measure-
ment error, practice eﬀects, and importantly rapidly
declining patients dropping out of the study which
there was evidence of in our SCANS cohort. In add-
ition, rates may diﬀer in diﬀerent patient cohorts with
individuals in the more advanced stages of cognitive
impairment tending to decline faster. However, what-
ever the reason, the diﬃculty detecting cognitive change
highlights the need for more sensitive ways to detect
change and allow screening of novel therapies in smal-
ler number and short follow-up periods.
A useful surrogate marker needs to be both sensitive
to change and to correlate with meaningful clinical out-
comes. In this study, WMH volume and the diﬀusion
parameter, MD NPH, were most sensitive to change
and therefore had the smallest sample size estimates.
In contrast to a previous smaller study with shorter
follow-up,12 DTI markers would require slightly
larger sample sizes than WMH, but further data are
required on the relative sensitivity of the two measures
to white matter damage.
The available evidence indicates that the MRI mar-
kers investigated in this study do correlate with clinical
outcomes as outlined in the introduction. Although
WMH volume has been shown to be associated with
cognitive impairment, these associations have been
inconsistent and weak,5,33 particularly in patients with
more severe disease and conﬂuent WMHs at study
entry.12 This was also the case in the baseline data
from the SCANS cohort used in this study.8 Brain
volume and DTI parameters show stronger associ-
ations with cognitive impairment,8,34 suggesting they
may represent clinically meaningful surrogate markers.
Deciding which markers are most useful can only be
deﬁnitively evaluated by including them in clinical
trials and determining which correlate most closely
with treatment eﬀects measured using clinical end
points. A combination of these MRI measures (i.e., a
composite score) may oﬀer a more sensitive approach;
however, whether such a parameter is able to predict
change in a clinical outcome measure longitudinally is
Table 5. Sample size estimates for MRI markers using all available data (four time points) compared with sample size estimates using
data only from two time points.
Variable
Percentage
difference
in the slope
Minimum sample size
per arm (using all
four time points)
Minimum sample
size per arm
(using only baseline
and 3-year data)
Minimum sample
size per arm
(using only baseline
and 2-year data)
WMH volume (30%) 124 61 72
(25%) 178 88 104
(20%) 279 137 162
(15%) 496 244 287
MD NPH (30%) 128 138 261
(25%) 185 199 375
(20%) 289 311 587
(15%) 513 553 1,044
Brain volume (30%) 145 106 97
(25%) 208 152 140
(20%) 325 238 219
(15%) 578 423 388
Abbreviations: MD NPH, mean diffusivity normalized peak height; MRI, magnetic resonance imaging; WMH, white matter hyperintensity. The final
column shows sample size estimates if patients were followed up for only 2 years.
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yet to be determined. In addition, the relative sensitivity
of clinical end points such as progression to disability
and dementia will need to be assessed in larger cohorts
with longer follow-up.
Because of the constraints of longitudinal follow-up
and the cost of MRI scanning in a clinical trial, it is
often not practical to collect MRI data for >2 time
points. We therefore performed additional analyses to
determine whether using MRI data from only two time
points aﬀected the sample size estimates. We found that
sample size estimates for WMH appear slightly smaller
when only data from baseline and 3 year follow-up are
considered but remain largely similar for brain volume
and MD NPH. This suggests that this approach is feas-
ible and has similar power for clinical trials; however, it
is important to be aware that these two time point
models are more susceptible to noise and data MAR.
In studies using MRI data from only two time points,
the interval must always be long enough for suﬃcient
change to accumulate and be detectable above the noise
that is inevitable whenever measurements are made.
This is evident from the higher estimated sample sizes
with 2 vs. 3 year follow-up.
It is important to carefully deﬁne and identify suit-
able cases for clinical trials in SVD. The heterogeneous
nature of SVD is a major hindrance to this. The cere-
bral small vessels can be aﬀected by a wide range of
pathologies, including cerebral amyloid angiopathy,
immunologically mediated diseases, and genetic
SVDs, such as CADASIL.1 The most common type,
however, is age-related and vascular risk factor-related
SVD. There is increasing evidence to suggest that even
this type of SVD may have multiple pathologies. It has
been suggested there are at least two underlying arterial
pathologies: microatheroma primarily causing larger,
usually isolated lacunar infarcts and a diﬀuse arterio-
pathy characterized by arteriolosclerosis, lipohyalino-
sis, or ﬁbrinoid necrosis (depending on severity of the
abnormality), which is thought largely to result from
hypertension and is associated with multiple smaller
lacunar infarcts and leukoaraiosis.35,36 This distinction
is supported by pathologic, radiologic, and risk factor
data.37 In view of these possible diﬀerences and to
study a homogenous group of patients, we recruited
only patients with symptomatic lacunar infarction con-
ﬁrmed on MRI as well as conﬂuent leukoaraiosis.
CMBs are a feature of SVD that are thought to vary
in their distribution depending on the underlying dis-
ease process,16 although their prognostic signiﬁcance
remains uncertain. We have analyzed CMBs in the
baseline data and shown a weak correlation with cog-
nition,38 but longitudinal data on CMBs were not avail-
able for this analysis. Therefore, we were unable to
determine sample size measures based on this imaging
parameter.
A major limitation of this study was that we had a
relatively high dropout rate, although this is consistent
with previous longitudinal studies in ageing.39 Patients
who did not complete follow-up tended to be older and
more disabled. This may have led to an underestima-
tion of the rate of change in MRI markers and cogni-
tion. Optimal trial design has to take careful
consideration of issues such as the dropout rate and
increase sample sizes accordingly. Errors in image pro-
cessing and registration are inevitable when attempting
to quantify MRI markers in a standardized manner.
This will increase noise in the data and reduce sensitiv-
ity to change. For example, the reported error of
SIENA is 0.15%. It is therefore unreliable when the
mean diﬀerence between groups is <0.2%. In addition,
measurement error may be higher when these markers
are used in a multicenter trial with imaging on diﬀerent
scanners. Because of the heterogeneous nature of the
disease, it is possible that in some patients MRI mar-
kers have plateaued to maximal impairment or have
not yet changed appreciably (ceiling and ﬂoor eﬀects,
respectively). Studies with longer follow-up may be cap-
able of identifying these patients and capture potential
non-linear aspects of change. Finally, these data were
acquired on a 1.5-Tesla MRI scanner. The quality and
precision of data might be improved by acquiring data
using sequences with isotropic voxel dimensions, at
higher resolutions, and MRI ﬁeld strengths.40
In conclusion, MRI is promising as a potential sur-
rogate marker in SVD. It is much more sensitive to
change than cognitive measures over a relatively short
time period. Optimizing and validating these markers
could signiﬁcantly reduce the size, duration, and cost of
clinical trials. Further studies evaluating these markers
and particularly relating them to clinical and cognitive
outcomes in longitudinal studies are required, and this
would ideally be done within the context of a rando-
mized clinical trial.
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